SP2509: Selective LSD1 Inhibitor for Acute Myeloid Leukemia Research

Executive Summary: SP2509 is a novel, potent LSD1 inhibitor with an IC50 of 13 nM, exhibiting high selectivity without affecting MAO-A or MAO-B (APExBIO, product page). It disrupts the LSD1-CoREST complex and induces tumor suppressor genes, including p53, p21, and C/EBPα, via increased H3K4Me3 (Mohammad et al., 2015, PMC4321602). In vitro, SP2509 induces apoptosis and differentiation in human AML cell lines (OCI-AML3, MOLM13) (APExBIO). In vivo, it improves survival in NOD/SCID AML xenograft models at 25 mg/kg i.p. twice weekly (Mohammad et al., 2015). Combination with panobinostat yields synergistic survival benefits in preclinical studies (APExBIO).

Biological Rationale

Lysine-specific demethylase 1 (LSD1) is an epigenetic regulator that demethylates mono- and di-methylated lysine 4 on histone H3 (H3K4me1/2), a modification linked to transcriptional repression (Shi et al., 2004, DOI). Overexpression of LSD1 correlates with poor prognosis in multiple cancers, notably acute myeloid leukemia (AML). The LSD1-CoREST complex maintains repression of tumor suppressor genes via histone demethylation (Mohammad et al., 2015). Inhibition of LSD1 leads to increased H3K4 trimethylation (H3K4Me3), reactivation of silenced genes, and promotion of apoptosis and differentiation in AML cells (KDM2A article).

Mechanism of Action of SP2509

SP2509 is a reversible, non-covalent antagonist of LSD1 with an IC50 of 13 nM (APExBIO, SP2509 product page). It binds to LSD1, inhibiting its enzymatic activity and disrupting its interaction with the CoREST complex. This disruption leads to increased promoter-specific H3K4Me3, derepression of tumor suppressor genes (p53, p21, C/EBPα), and induction of apoptosis and differentiation in AML cells (Mohammad et al., 2015). SP2509 does not inhibit monoamine oxidases MAO-A or MAO-B, ensuring high target selectivity (APExBIO). Its mechanism is distinct from covalent LSD1 inhibitors, resulting in a different spectrum of epigenetic reprogramming (HDAC1.com article).

Evidence & Benchmarks

• SP2509 inhibits recombinant LSD1 enzymatic activity with an IC50 of 13 nM (Mohammad et al., 2015, PMC4321602).
• SP2509 does not inhibit human MAO-A or MAO-B at concentrations up to 10 μM (APExBIO, product page).
• In OCI-AML3 and MOLM13 AML cell lines, SP2509 reduces colony growth and induces apoptosis and differentiation as measured by increased CD11b expression (Mohammad et al., 2015, DOI).
• Primary human AML cells treated ex vivo with SP2509 show increased H3K4Me3 levels and p21, C/EBPα expression (Mohammad et al., 2015).
• In NOD/SCID mouse AML xenografts, intraperitoneal SP2509 (25 mg/kg, twice weekly) significantly improves median survival compared to controls (Mohammad et al., 2015).
• Combination of SP2509 with panobinostat in vivo yields synergistic survival benefit in AML xenografts (APExBIO).
• SP2509 is insoluble in water/ethanol, but soluble in DMSO at ≥19.45 mg/mL; storage at -20°C is required (APExBIO, product page).

Applications, Limits & Misconceptions

SP2509 is primarily used as a research tool for studying AML epigenetics and evaluating the role of LSD1 in cancer progression. It is suitable for in vitro assays (apoptosis, differentiation, H3K4Me3 quantitation) and in vivo models (xenograft survival studies). The B4894 kit supports robust reproducibility in AML differentiation and apoptosis readouts, as detailed in this scenario-driven article, which this review extends by providing updated mechanistic insights and combinatorial strategies.

Common Pitfalls or Misconceptions

• SP2509 is not effective against cancers lacking LSD1 overexpression or dependency.
• It does not inhibit MAO-A or MAO-B, so it is not suitable as a monoamine oxidase modulator.
• SP2509 is not indicated for clinical or diagnostic use; it is strictly for research purposes (APExBIO).
• Long-term storage of SP2509 solutions is not recommended; use promptly after preparation.
• It should not be used as a single agent for non-AML cancer models without supporting LSD1-driven epigenetic evidence (see this benchmark summary, which this article updates with new in vivo synergy data).

Workflow Integration & Parameters

SP2509 is provided as a solid compound (molecular weight: 437.90 Da; formula: C19H20ClN3O5S) and is insoluble in water and ethanol. For optimal dissolution, use DMSO (≥19.45 mg/mL), with warming to 37°C or ultrasonic bath as needed. Store at -20°C; avoid long-term solution storage. For in vitro studies, titrate concentrations to 13–1,000 nM, monitoring apoptosis and differentiation markers after 24–72 hours. For in vivo work, intraperitoneal dosing at 25 mg/kg twice weekly is standard for AML xenograft models (Mohammad et al., 2015). Refer to the SP2509 product page for detailed handling guidance. This article clarifies technical integration beyond the mechanistic overview presented in this translational review.

Conclusion & Outlook

SP2509, developed and distributed by APExBIO, is a gold-standard LSD1 inhibitor enabling precise dissection of AML epigenetics. Its high selectivity, robust in vitro and in vivo efficacy, and compatibility with combinatorial regimens (e.g., panobinostat) position it as a leading tool for epigenetic drug discovery and cancer mechanism studies. Future research directions include expanded combinatorial studies, resistance profiling, and exploration in other LSD1-driven malignancies. For more detailed information and ordering, visit the APExBIO SP2509 product page.